Migra Therapeutics, an Atlanta-based medical organization, innovates nanotech therapies for effective cancer treatment.
Migra Therapeutics, founded by Drs. Lily Yang and Lei Zhu in Atlanta, Georgia, is a biopharmaceutical company dedicated to the clinical translation and commercialization of innovative drug delivery systems. Their core mission is to develop and implement nanotechnology-based therapies to combat cancer more effectively. The company focuses on creating targeted nanoparticles that can penetrate dense cancer cell barriers, such as stroma in pancreatic and breast cancers, to deliver chemotherapy drugs and therapeutic antibodies more efficiently.
Notable figures affiliated with Migra Therapeutics include its founders, Drs. Lily Yang and Lei Zhu, who are also researchers at Emory University. The company has made significant strides in the field of targeted drug delivery, leveraging their academic research to create practical medical solutions. Their innovative approach has the potential to revolutionize cancer treatment by improving drug efficacy and reducing side effects, thereby making a substantial impact on patient outcomes.

ZY Therapeutics
zytinc.com

Micron Biomedical

NanoMedical Systems
nanomedsys.com

Tiny Cargo
tinycargo.com

Cello Therapeutics
cellothera.com
SynerGene Therapeutics

Nirogy Therapeutics

Advanced NanoTherapies
Talima Therapeutics
talima.com

Etira
etira.life

PanTher Therapeutics
panthertx.com

Mechano-Therapeutics

Paramita Therapeutics

Seurat Therapeutics

NanoPharmaceuticals

Tigris Pharmaceuticals
tigrispharma.com
Curamir Therapeutics

LifeBridge Innovations

NanoMedTrix

Nanocan Therapeutics
nanocan.life
Migra Therapeutics' most recent funding round was for $51.7k (USD) in January 2019.
As of Jan 22, 2019, Migra Therapeutics has disclosed funding of $87.5k (USD).